Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Pivotal Trial The First For A Dual Inhibitor
Executive Summary
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
You may also be interested in...
Daiichi Sankyo Plays Long Game With Quizartinib Outside Japan
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset
AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.